Ursula A. Matulonis, MD, on Key Findings With Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.

Ursula A. Matulonis, MD, Brock-Wilson Family Chair and chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School, spoke with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer about key findings from the phase 3 SORAYA trial (NCT04296890)exploring efficacy of mirvetuximab soravtansine (IMGN853) in patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

In addition to describing the therapy’s mechanism of action, Matulonis highlighted the promising response rates it yielded. She also discussed a subgroup analysis in which responses were examined among patients who had previously received a PARP inhibitor.


Mirvetuximab soravtansine is an antibody-drug conjugate that has the antibody to FRα. There’s a cleavable linker. It’s linked to maytansinoid DM4, which is a potent anti-tubulin agent. Patients had platinum-resistant, ovarian cancer—all [had] high-grade serous [disease and had] received prior bevacizumab [Avastin] and up to 3 lines of treatment.

We were aiming to have a 24% response rate vs a 12% response rate because that’s what is seen with single-agent chemotherapy in platinum-resistant ovarian cancer. But what we saw was a 32.4% confirmed overall response rate with 5 complete responses and 29 partial responses. [We are] really pleased with the overall response rate. Additionally, we saw a duration of response of 6.9 months, which was great. Both the overall response rate of 32.4% and the duration of response of 6.9 months held up in 2 predefined subgroups, [including] those [with] 2 prior lines of treatment vs 3 prior lines of treatment. The second subgroup analysis was around prior PARP or no prior PARP inhibitor, so it didn’t matter if patients were more heavily pretreated or if they had received a prior PARP inhibition. They had response rates that were, again, not affected by being more heavily pretreated or having received a prior PARP inhibitor.


Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 SGO Annual Meeting on Womens’ Cancers; March 18-21, 2022; Phoenix, AZ. Abstract 242.

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.